Cellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual Meeting

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...
Santé log

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保) ...

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for ...
News-Medical.Net on MSN

Gut microbe metabolite TMA improves blood sugar by shutting down a key inflammatory switch

Researchers identified trimethylamine (TMA) as a gut microbe–derived metabolite that directly inhibits IRAK4 to reduce ...

Researchers find vital clue in the progression of Type 1 diabetes

Type 1 diabetes is a disease in which the body mistakenly attacks itself as the immune system destroys the pancreas's insulin ...